Safety of Lanreotide 120 mg ATG in Combination With Metformin in Patients With Progressive Advanced Well-differentiated Gastro-intestinal (GI) or Lung Carcinoids: A Pilot, One-arm, Open-label, Prospective Study: the MetNET-2 Trial

Trial Profile

Safety of Lanreotide 120 mg ATG in Combination With Metformin in Patients With Progressive Advanced Well-differentiated Gastro-intestinal (GI) or Lung Carcinoids: A Pilot, One-arm, Open-label, Prospective Study: the MetNET-2 Trial

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Lanreotide (Primary) ; Metformin
  • Indications Gastrointestinal cancer; Lung cancer
  • Focus Adverse reactions
  • Acronyms MetNET-2
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Sep 2016 Data from this trial will be presented at the European Society for Medical Oncology (ESMO) 2016 Congress, reported in an Ipsen media release.
    • 13 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top